Amgen Seeks 1st Biosimilar Of Mega-Blockbuster Humira
Amgen has submitted its long-awaited application for a biosimilar of AbbVie's mega-blockbuster Humira, the world's best-selling prescription drug and the sort of highly complex product that presents major scientific challenges for...To view the full article, register now.
Already a subscriber? Click here to view full article